key: cord-0826933-6ohxj27a authors: Weis, Sebastian; Scherag, André; Baier, Michael; Kiehntopf, Michael; Kamradt, Thomas; Kolanos, Steffi; Ankert, Juliane; Glöckner, Stefan; Makarewicz, Oliwia; Hagel, Stefan; Bahrs, Christina; Kimmig, Aurelia; Proquitté, Hans; Guerra, Joel; Rimek, Dagmar; Löffler, Bettina; Pletz, Mathias W. title: Antibody response using six different serological assays in a completely PCR-tested community after a COVID-19 outbreak - The CoNAN study date: 2020-11-20 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2020.11.009 sha: 700a21efebcb75dd3e5b5cfbf3e91a90389b42fd doc_id: 826933 cord_uid: 6ohxj27a OBJECTIVES: Due to a substantial proportion of asymptomatic and mild courses, many SARS-CoV-2 infections remain unreported. Therefore, assessment of seroprevalence may detect the real burden of disease. We aimed at determining and characterizing the rate of SARS-CoV-2 infections and the resulting seroprevalence in a defined population. The primary objective of the study was to assess SARS-CoV-2 antibody seroprevalence using six different IgG detecting immunoassays. Secondary objectives of the study were: i.) to determine potential risk factors for symptomatic vs. asymptomatic Covid19 courses; ii.) to investigate the rate of virus RNA-persistence. METHODS: CoNAN is a population-based cohort study performed in the community Neustadt am Rennsteig, Germany that was quarantined from March 22(nd) to April 5(th) after six SARS-CoV-2 cases were detected in the villages’ population. The SARS-CoV-2 outbreak compromised 51 cases and 3 deaths. The CoNAN study was performed from May 13th to May 22nd 2020 six weeks after a SARS-CoV-2 outbreak. RESULTS: We enrolled a total of 626 participants (71% of the community population) for PCR- and antibody testing in the study. All actual SARS-CoV-2 PCR tests were negative. Fifty-two out of 620 (8.4%) participants had antibodies against SARS-CoV-2 in at least two different assays. There were 38 participants with previously PCR-confirmed SARS-CoV-2 infection. Of those, only 19 (50%) displayed anti-SARS-CoV-2 antibodies. We also show that antibody positive participants with symptoms compatible with a respiratory tract infection had significantly higher antibody levels then asymptomatic participants (EU-assay: Median 2.9 vs. 7.2 IgG-index, p=0.002; DS-assay: Median 45.2 vs. 143 AU/mL, p=0.002). Persisting viral replication was not detected. CONCLUSIONS: Our data question the relevance and reliability of IgG antibody testing to detect past SARS-CoV-2 infections six weeks after an outbreak. We conclude that assessing immunity for SARS-CoV-2 infection should not only rely on antibody tests. SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) is a pandemic pathogen with 109 transmission by droplets and aerosols It has been argued, that the risk to acquire the infection 110 is minimized if a large percentage of the population has been infected with SARS-CoV-2 and 111 has, at least partially, developed immunity against it [1] . Several population-based cohort approximately six weeks after a mass testing in the village was performed ( Figure 1 ). The 139 study was set-up after the mass-testing results were obtained. After informed consent, 140 questionnaires, blood samples and pharyngeal washes were directly taken at the study site. Pharyngeal washes were obtained by 10-20 s gargling of 10 mL 0.9 NaCL after rinsing the 142 mouth with 50 mL non-sparkling commercial water. At the study site, blood was directly centrifuged at 4°C/2,000 g for 10 minutes and stored at 144 8°C. Pharyngeal washes were obtained after a short mouth wash with non-sparkling water 145 under direct supervision of a study team member to ensure appropriate quality. Characteristics of the participants are given in Table 1 Table 227 1, Supplementary Table 2) . In 26 participants, only 1 out of 6 assays was positive. These patients were judged to reflect 229 uncertain cases and assessed as sero-negative for the comparison. Of those, three had are shown in Figure 4a . For seropositive participants, we also assessed whether extent of the 260 antibody response differed between symptomatic and asymptomatic individuals. Data is shown for the two of the assays (Figure 4b-e) . Symptomatic individuals showed a significantly This study has several limitations: i.) our study was a population-based cohort study. We were 314 able to recruit 71% of the community population. However, 29% of the population did not Herd Immunity: Understanding COVID-19 Evaluation of SARS-CoV-2 serology assays reveals a range of test performance immunoassays in comparison with microneutralisation Seroepidemiology-2020.1-eng.pdf?sequence=1&isAllowed=y Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric 407 SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-414 sectional study A 418 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of 419 protection, and association with severity Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 423 patients Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody 431 responses during infection by SARS-CoV-2: an observational cohort study Antibody Detection and Dynamic Characteristics in Patients with 435 COVID-19 Convergent antibody responses to 443 SARS-CoV-2 in convalescent individuals Clinical 446 and immunological assessment of asymptomatic SARS-CoV-2 infections Antibody Responses to SARS-CoV-2 at 8 Weeks 449 Postinfection in Asymptomatic Patients Duration of antibody responses after severe acute respiratory syndrome Estimating the 458 infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data 459 from the outbreak on the Diamond Princess cruise ship CoV: Implications for vaccine development against MERS-CoV Immunology of COVID-19: Current State of the Science The Immunobiology of SARS* Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses